Please provide your email address to receive an email when new articles are posted on . Among patients with ACS who received an infusion of bivalirudin after PCI, those who had a full dose showed ...
CHICAGO -- Periprocedural anticoagulation with bivalirudin (Angiomax) for a radial-first approach to primary percutaneous coronary intervention (PCI) improved mortality and bleeding risk compared with ...
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo urgent percutaneous coronary intervention (PCI), and ...
PARIS--(BUSINESS WIRE)-- During the Late Breaking Clinical Trial sessions at EuroPCR yesterday and published simultaneously in the European Heart Journal, Professor Uwe Zeymer of Klinikum Ludwigshafen ...
The 6000-patient BRIGHT-4 trial from China is prompting a rethink on bivalirudin in cath labs around the world and whether it should be the first-choice anticoagulant in primary percutaneous coronary ...
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo urgent percutaneous coronary intervention (PCI), and ...
A new study could change the treatment course for hundreds of thousands of patients, saving lives and preventing complications. Bivalirudin is a safer and more effective anticoagulant than heparin for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results